A new study led by Washington University and published in Nature – Vaccines,  highlights the use of C3P3 technology in vaccine research targeting rotaviruses. These viruses, which cause severe gastroenteritis, remain a major cause of infant mortality in developing countries.

The publication shows how C3P3 was used to produce the studied rotaviruses and highlights the greater efficiency gains brought by a more advanced C3P3 prototype (initial version of C3P3-G3) than the one used in previous studies by Stanford researchers (C3P3-G1).

For more information on the use of C3P3 in rotavirus vaccine research, see these previous publications:

https://pubmed.ncbi.nlm.nih.gov/32759316/

https://pubmed.ncbi.nlm.nih.gov/36821582/

Note: The commercial model of C3P3 further outperforms the prototypes.